1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid benzyl amide | 448968-75-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid benzyl amide
• 英文别名: N-benzyl-1-methyl-2,4-dioxothieno[3,2-d]pyrimidine-6-carboxamide
• CAS: 448968-75-0
• 化学式: C₁₅H₁₃N₃O₃S
• 分子量: 315.353
• InChiKey: LQZKMDASIQNBJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  107
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid 、 苄胺 、 N,N-二异丙基乙胺 、 O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 在 乙醇 、 正戊烷 作用下， 以 N,N-二甲基甲酰胺 、 乙醇 为溶剂， 反应 17.0h， 以to yield 33.8 mg (70%) of 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid benzyl amide as a white solid的产率得到1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid benzyl amide
  参考文献：
  名称：

  Fused pyrimidinone matrix metalloproteinase inhibitors

  摘要：

  选择性MMP-13抑制剂是式1的融合嘧啶酮或其药学上可接受的盐，其中：W与其连接的碳原子形成一个5元环二自由基2X为O、S、SO、SO2、NR5或CH2；3B为O或NR5；或A和B结合形成—C≡C—；R1、R4和R5为氢、烷基、烯基、炔基、(CH2)n芳基、(CH2)n环烷基、C1-C6烷酰基或(CH2)nheteroaryl；R2和R3为氢、烷基、烯基、炔基、CN、NO2、NR4R5、(CH2)n环烷基、(CH2)n芳基或(CH2)nheteroaryl；R2还可以是卤素；n为0到5的整数；当R4和R5与它们都连接的氮一起形成含碳原子的3-8元环时，该环可以选择性地含有O、S或N，且可能被取代或未取代；但是R1和R3不能同时选择自氢和C1-C6烷基。

  公开号：

  US20030004172A1

文献信息

• EP1229910A4
  申请人：——

  公开号：EP1229910A4

  公开（公告）日：2003-10-01
• INTEGRIN RECEPTOR ANTAGONISTS
  申请人：Merck & Co., Inc.

  公开号：EP1229910A1

  公开（公告）日：2002-08-14
• THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS
  申请人：Warner-Lambert Company LLC

  公开号：EP1370562A1

  公开（公告）日：2003-12-17
• [EN] INTEGRIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RECEPTEURS D'INTEGRINE
  申请人：MERCK & CO INC

  公开号：WO2001024797A1

  公开（公告）日：2001-04-12

  The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and/or αvβ5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.
• [EN] THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] DERIVES DE THIENO'2,3-D PYRIMIDINONE UTILISES COMME INHIBITEURS DE METALLOPROTEINASES MATRICIELLES
  申请人：WARNER LAMBERT CO

  公开号：WO2002064598A1

  公开（公告）日：2002-08-22

  Selective MMP-13 inhibitors are fused pyrimidinones of the formula or a pharmaceutically acceptable salt thereof, wherein: W, together with the carbon atoms to which it is attached, form a 5-membered ring diradical Y is O, S, SO, SO2, NR5, or CH¿2, ?A is-C-or S-; B is O or NR?5¿; or A and B are taken together to form -C C-; R?1, R4, and R5¿ are hydrogen, alkyl, alkenyl, alkynyl, (CH¿2?)n aryl, (CH2)n cycloalkyl, C1 C6 alkanoyl, or (CH2)n heteroaryl; R?2 and R3¿ are hydrogen, alkyl, alkenyl, alkynyl CN, NO¿2?, NR?4R5, (CH¿2)n cycloalkyl, (CH2)n aryl, or (CH2)n heteroaryl; R2 may further be halo; n is an integer of from 0 to 5; and R?4 and R5¿ when taken together with the nitrogen to which they are attached complete a 3-to 8-membered ring containing carbon atoms and optionally containing O, S, or N, and substituted or unsubstituted; with the proviso that R?1 and R3¿ are not both selected from hydrogen and C¿1-?C6 alkyl.